Johnson & Johnson Innovative Medicine Hematology Request for Proposals
Supports implementation science and educational projects to improve bispecific antibody therapy care for relapsed/refractory multiple myeloma patients in community healthcare settings.
Funder: Johnson & Johnson (Janssen)
Due Dates: June 30, 2026 (Implementation Science RFP)
Funding Amounts: Up to $275,000 per project; lower-cost projects prioritized; maximum project duration 18 months
Summary: Funds implementation science–driven educational initiatives to improve care for relapsed/refractory multiple myeloma patients eligible for bispecific antibody therapy in community healthcare settings.
Key Information: General research grants are not eligible—projects must embed certified education (CME/CE) within operational improvements.
Description
This grant opportunity supports implementation science–driven educational initiatives aimed at optimizing the treatment and care of patients with relapsed/refractory multiple myeloma (RR/MM) who are eligible for bispecific antibody (BsAb) therapy. The focus is on embedding certified education (CME/CE) within broader operational and collaborative strategies to drive measurable improvements in care processes, clinician behavior, and patient outcomes in community-based healthcare organizations.
Projects should implement and evaluate practice-level or system-level changes, engage cross-functional teams (e.g., hematology/oncology, pharmacy, nursing, administration), and align educational interventions with practical improvements in cancer centers or health systems. Sustainability of changes, clear success metrics, and wide dissemination of findings are required. Research-only projects are not eligible.
